ライフサイエンスコーパス: sclerosing

1 We reported on two patients with sclerosing adenosis assessed with mammography, ultrasoun

2 Sclerosing adenosis does not have distinctive radiologic

3 Sclerosing adenosis is a benign, usually asymptomatic lo

4 Sclerosing adenosis proved to be a minor component at co

5 Sclerosing adenosis was a major (> or =50%) component fo

6 base of 1,166 percutaneous biopsies in which sclerosing adenosis was reported, 88 (7.5%) lesions were

7 ith 33 lesions without atypia or malignancy, sclerosing adenosis was the major finding at core biopsy

8 Malignancy can be seen with sclerosing adenosis; core biopsy was accurate in six (86

9 filling targeted vascular malformations with sclerosing agent.

10 of visceralized parietal epithelial cells in sclerosing and collapsing lesions in a kidney biopsy fro

11 gioma responded to sildenafil after repeated sclerosing and drainage procedures failed to achieve rem

12 vior and histopathologic features of nodular-sclerosing and papillary tumors were assessed.

13 Germline WTX mutations cause an X-linked sclerosing bone dysplasia but do not appear to predispos

14 n the sclerosteosis gene (SOST) cause a rare sclerosing bone dysplasia characterized by skeletal over

15 ffected by Van Buchem (VB) disease, a severe sclerosing bone dysplasia.

16 Sclerosing cases were associated with an insidious onset

17 primary biliary cirrhosis (16%), and primary sclerosing cholangitis (13%) with an odds ratio of 2.3,

18 ancies (46.4%) and 114 patients with primary sclerosing cholangitis (62.3%).

19 Primarily indications for ERC were sclerosing cholangitis (75%) and malignant stenosis (9.5

20 in autoimmune hepatitis (AIH) and autoimmune sclerosing cholangitis (AISC) either through inability o

21 ary sclerosing cholangitis (PSC), autoimmune sclerosing cholangitis (ASC), and autoimmune hepatitis (

22 cholangitis (IAC), also called IgG4-related sclerosing cholangitis (IRSC), to the spectrum of chroni

23 era from patients with PBC (n = 47), primary sclerosing cholangitis (n = 15), and healthy volunteers

24 ancreatitis (n = 34) from those with primary sclerosing cholangitis (n = 17) and CA (n = 17).

25 ra from patients with PBC (n = 105), primary sclerosing cholangitis (n = 70), and rheumatoid arthriti

26 Strictures in patients with primary sclerosing cholangitis (n = 86) were analyzed separately

27 he causes of death were related to secondary sclerosing cholangitis (n=1), cardiac failure (n=1), and

28 imary biliary cirrhosis (PBC, n=76), primary sclerosing cholangitis (n=81), hepatitis C virus (HCV) (

29 Neonatal ichthyosis and sclerosing cholangitis (NISCH) syndrome is a liver disea

30 all P = .003), as well as absence of primary sclerosing cholangitis (P = .011).

31 tis C virus (P = 0.01, HR = 1.6) and primary sclerosing cholangitis (P = 0.03, HR = 2.9).

32 The prevalence of primary sclerosing cholangitis (PSC) among patients with inflamm

33 primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) and assessed both vertebral

34 sis occurs during the progression of primary sclerosing cholangitis (PSC) and is characterized by acc

35 Primary sclerosing cholangitis (PSC) and primary biliary cholang

36 ding bile duct epithelium) varies in primary sclerosing cholangitis (PSC) and primary biliary cirrhos

37 Patients with primary sclerosing cholangitis (PSC) are at an increased risk fo

38 Patients with primary sclerosing cholangitis (PSC) are at increased risk for d

39 Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are infrequent autoimmune c

40 tologic scoring systems specific for primary sclerosing cholangitis (PSC) are not validated.

41 primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC) are scarce.

42 Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are uncommon liver diseases

43 s serum liver tests in patients with primary sclerosing cholangitis (PSC) but does not improve surviv

44 eased donor livers for patients with primary sclerosing cholangitis (PSC) due to the weighting of the

45 proximately 60%-80% of patients with primary sclerosing cholangitis (PSC) have concurrent ulcerative

46 giography (MRC) for the diagnosis of primary sclerosing cholangitis (PSC) have described comparable a

47 developing varices in patients with primary sclerosing cholangitis (PSC) have not been well studied

48 The epidemiology of primary sclerosing cholangitis (PSC) in the United States is unk

49 Primary sclerosing cholangitis (PSC) is a chronic bile duct dise

50 Primary sclerosing cholangitis (PSC) is a chronic cholestatic di

51 Primary sclerosing cholangitis (PSC) is a chronic cholestatic li

52 Primary sclerosing cholangitis (PSC) is a chronic cholestatic li

53 Primary sclerosing cholangitis (PSC) is a chronic cholestatic li

54 Primary sclerosing cholangitis (PSC) is a chronic fibroinflammat

55 Primary sclerosing cholangitis (PSC) is a chronic, fibroinflamma

56 Primary sclerosing cholangitis (PSC) is a chronic, idiopathic, f

57 Primary sclerosing cholangitis (PSC) is a rare but important liv

58 Primary sclerosing cholangitis (PSC) is a rare progressive disor

59 Primary sclerosing cholangitis (PSC) is a rare, but serious, cho

60 Primary sclerosing cholangitis (PSC) is a severe liver disease o

61 Primary sclerosing cholangitis (PSC) is an incurable cholangiopa

62 BACKGROUND & AIMS: Primary sclerosing cholangitis (PSC) is an orphan hepatobiliary

63 Primary sclerosing cholangitis (PSC) is increasingly diagnosed i

64 Patients with primary sclerosing cholangitis (PSC) may be at higher risk of ma

65 Patients with primary sclerosing cholangitis (PSC) may develop and bleed from

66 Pathogenesis of primary sclerosing cholangitis (PSC) may involve impaired bile a

67 features of patients with small-duct primary sclerosing cholangitis (PSC) occurring with and without

68 stricture formation in patients with primary sclerosing cholangitis (PSC) or after liver transplantat

69 ed specifically in cholangiocytes of primary sclerosing cholangitis (PSC) patients and in mice subjec

70 Primary sclerosing cholangitis (PSC) patients pose a particularl

71 Primary sclerosing cholangitis (PSC) patients suffer from comorb

72 o summarize publications on juvenile primary sclerosing cholangitis (PSC) published over the past 5 y

73 The pathogenesis of primary sclerosing cholangitis (PSC) remains poorly understood.

74 For patients with primary sclerosing cholangitis (PSC) suffering from bacterial ch

75 Primary sclerosing cholangitis (PSC) was present in 31/126 CCA p

76 mens, including 64 with PBC, 19 with primary sclerosing cholangitis (PSC), 6 with non-A, non-B hepati

77 Primary sclerosing cholangitis (PSC), a chronic inflammatory liv

78 Primary sclerosing cholangitis (PSC), age, history of cholecyste

79 ects, including 28 with PBC, 13 with primary sclerosing cholangitis (PSC), and 18 healthy controls.

80 ses primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), and alcoholic liver diseas

81 Several conditions, such as primary sclerosing cholangitis (PSC), are risk factors.

82 atic tissue from patients with AP or primary sclerosing cholangitis (PSC), as well as from mice.

83 ogy and natural history of pediatric primary sclerosing cholangitis (PSC), autoimmune sclerosing chol

84 In primary sclerosing cholangitis (PSC), bile fluid is frequently c

85 bowel disease may be accompanied by primary sclerosing cholangitis (PSC), but seldom primary biliary

86 arly primary biliary cholangitis and primary sclerosing cholangitis (PSC), evolve over time with anat

87 Primary sclerosing cholangitis (PSC), first described in the mid

88 for detecting cholangiocarcinoma in primary sclerosing cholangitis (PSC), particularly when used seq

89 primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC), results from an impairment

90 iated biliary injury is a feature of primary sclerosing cholangitis (PSC).

91 e, other benign disease, tumour, and primary sclerosing cholangitis (PSC).

92 or management of adult patients with primary sclerosing cholangitis (PSC).

93 andard of reference for diagnosis of primary sclerosing cholangitis (PSC).

94 n of cholangiopathies, in particular primary sclerosing cholangitis (PSC).

95 and disease course in patients with primary sclerosing cholangitis (PSC).

96 not been well studied in those with primary sclerosing cholangitis (PSC).

97 s; however, no information exists in primary sclerosing cholangitis (PSC).

98 deoxycholic acid (UDCA) for treating primary sclerosing cholangitis (PSC).

99 primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC).

100 ated inflammatory diseases including primary sclerosing cholangitis (PSC).

101 primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC).

102 iocyte senescence has been linked to primary sclerosing cholangitis (PSC).

103 fibrosis in animal models and human primary sclerosing cholangitis (PSC).

104 ng disease activity and prognosis in primary sclerosing cholangitis (PSC).

105 reported in 9%-15% of patients with primary sclerosing cholangitis (PSC); it is not clear whether th

106 ignancy was highest in patients with primary sclerosing cholangitis (PSC; 22% at 10 years) or alcohol

107 ary biliary cirrhosis (PBC; n=3052), primary sclerosing cholangitis (PSC; n=3854), hepatitis C virus

108 reater primary dysfunction GF, while primary sclerosing cholangitis (PSC; P=0.0002) implied greater v

109 carcinoma (HCC) (SMR 38.4-18.8), and primary sclerosing cholangitis (SMR 11.0-4.2), and deterioration

110 imary biliary cholangitis [PBC], and primary sclerosing cholangitis [PSC]), we built a comprehensive

111 Primary biliary cirrhosis, primary sclerosing cholangitis and biliary atresia are thought t

112 nd pancreas is difficult to distinguish from sclerosing cholangitis and biliary/pancreatic malignanci

113 re up-regulated by cholangiocytes in primary sclerosing cholangitis and cholangiocarcinoma.

114 Primary sclerosing cholangitis and immunosuppressive use were no

115 astic bile duct inflammatory disease primary sclerosing cholangitis and in human cholangiocarcinoma s

116 1.9, P < .005) and in patients with primary sclerosing cholangitis and in severity were independentl

117 ular, the strong comorbidity between primary sclerosing cholangitis and inflammatory bowel disease is

118 apies for primary biliary cirrhosis, primary sclerosing cholangitis and intrahepatic cholestasis.

119 AP in the bile ductular reactions of primary sclerosing cholangitis and primary biliary cirrhosis pat

120 immune-mediated diseases, including primary sclerosing cholangitis and primary biliary cirrhosis, bu

121 dylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis and ulcerative colitis to investi

122 lymphedema, protein loosing enteropathy, and sclerosing cholangitis and was diagnosed with lymphedema

123 en, with only 7 patients having a history of sclerosing cholangitis and/or inflammatory bowel disease

124 ncluding autoimmune hepatitis and autoimmune sclerosing cholangitis ASC).

125 sitive biliary strictures resembling primary sclerosing cholangitis but with increased serum immunogl

126 s liver fibrosis in a mouse model of primary sclerosing cholangitis by miR-200b down-regulation.

127 Differentiation of primary sclerosing cholangitis can be challenging because other

128 samples (15 CCAs and 20 nonmalignant primary sclerosing cholangitis controls), and the methylation st

129 arkers was validated (34 CCAs and 34 primary sclerosing cholangitis controls).

130 In a subgroup of patients, sclerosing cholangitis develops, which may lead to end-s

131 gram results, but the syndrome of autoimmune sclerosing cholangitis does not affect immediate prognos

132 ural history of large and small duct primary sclerosing cholangitis has been reviewed.

133 Patients with primary sclerosing cholangitis have a poor prognosis; progressio

134 f patients previously diagnosed with primary sclerosing cholangitis have autoimmune pancreatitis in a

135 s associated with protection against primary sclerosing cholangitis have been elucidated.

136 antigen haplotype associations with primary sclerosing cholangitis have been investigated.

137 e gene polymorphisms associated with primary sclerosing cholangitis have been investigated.

138 Liver histology of sclerosing cholangitis improved, and extent of fibrosis

139 Primary sclerosing cholangitis in children can mimic autoimmune

140 ctive and accurate way of diagnosing primary sclerosing cholangitis in comparison with endoscopic ret

141 id transporter (ASBT), blocks progression of sclerosing cholangitis in mdr2(-/-) mice.

142 higher rate of retransplantation for primary sclerosing cholangitis in most centers.

143 hepatitis in children may be associated with sclerosing cholangitis in the absence of inflammatory bo

144 Symptoms of primary sclerosing cholangitis include fatigue, jaundice, prurit

145 Primary sclerosing cholangitis is a chronic cholestatic disease

146 Primary sclerosing cholangitis is a chronic cholestatic liver di

147 Primary sclerosing cholangitis is a chronic cholestatic liver di

148 Primary sclerosing cholangitis is a chronic cholestatic liver di

149 Primary sclerosing cholangitis is a chronic cholestatic liver di

150 Primary sclerosing cholangitis is a chronic cholestatic liver di

151 Primary sclerosing cholangitis is a chronic immune-mediated live

152 Primary sclerosing cholangitis is a chronic, progressive cholang

153 The genetic susceptibility to primary sclerosing cholangitis is associated, in part, with the

154 Liver histology in primary sclerosing cholangitis is characterized by a portal infl

155 Treatment of primary sclerosing cholangitis is confined to supportive measure

156 ate that the colitis associated with primary sclerosing cholangitis is pathophysiologically distinct

157 ic heterogeneity among patients with primary sclerosing cholangitis is supported, and further gene po

158 Primary sclerosing cholangitis is the classic hepatobiliary mani

159 The etiopathogenesis of primary sclerosing cholangitis is unknown.

160 The best-studied drug in primary sclerosing cholangitis is ursodeoxycholic acid, which, d

161 PBC livers, compared with normal and primary sclerosing cholangitis livers.

162 It is suggested that primary sclerosing cholangitis may have a bacterial cause.

163 Primary sclerosing cholangitis may overlap with autoimmune hepat

164 Sclerosing cholangitis may recur after transplantation,

165 Primary sclerosing cholangitis mice and patients have increased

166 human liver samples from control or primary sclerosing cholangitis patients were evaluated for MC ma

167 s been demonstrated in a subgroup of primary sclerosing cholangitis patients, which may indicate an o

168 bile ducts from the hilar region of primary sclerosing cholangitis patients.

169 ve CCA detection, particularly among primary sclerosing cholangitis patients.

170 bacteria in the etiopathogenesis of primary sclerosing cholangitis remains to be determined.

171 le modeling using RC, FISH, age, and primary sclerosing cholangitis status can be used to estimate th

172 , trisomy FISH, suspicious cytology, primary sclerosing cholangitis status, and age were associated w

173 tween inflammatory bowel disease and primary sclerosing cholangitis underscores the need to further u

174 Cirrhosis not related to primary sclerosing cholangitis was associated with both intrahep

175 Primary sclerosing cholangitis was more strongly associated with

176 d inflammatory bowel disease without primary sclerosing cholangitis was not associated with any CCA s

177 A paucity of research studies on primary sclerosing cholangitis was noted in this review and futu

178 with inflammatory bowel disease and primary sclerosing cholangitis was the identification of an incr

179 For all recipients, female sex and primary sclerosing cholangitis were associated with improved sur

180 disease, and those with concomitant primary sclerosing cholangitis were at increased risk.

181 Patients suspected to have secondary sclerosing cholangitis were excluded.

182 second patient was a 26-year-old female with sclerosing cholangitis who presented with encephalopathy

183 ciated primary biliary cirrhosis and primary sclerosing cholangitis with genes encoding major histoco

184 itis with pancreatic pseudotumour, n = 7; e) Sclerosing cholangitis with hepatic pseudotumour, n = 3;

185 mples from patients with and without primary sclerosing cholangitis with higher levels of sensitivity

186 Sclerosing cholangitis with strong autoimmune features i

187 vs. 0.6%), hepatobiliary (including primary sclerosing cholangitis) (5.5% vs. 0.1%), pancreatic (1.7

188 rbonyl-1,4-dihydrocollidine (DDC; a model of sclerosing cholangitis) for 4 weeks.

189 4-dihydrocollidine (DDC) feeding (a model of sclerosing cholangitis) or bile duct ligation (BDL).

190 ther inflammatory disorders (such as primary sclerosing cholangitis), whereas it decreases when patie

191 ls with autoimmune diseases (18 with primary sclerosing cholangitis, 16 with autoimmune hepatitis, an

192 itis, extensive colonic involvement, primary sclerosing cholangitis, a family history of colorectal c

193 une pancreatitis in association with primary sclerosing cholangitis, a syndrome with distinct clinico

194 in CLDs (primary biliary cirrhosis, primary sclerosing cholangitis, alcoholic liver disease, and chr

195 ic cholestasis, biliary atresia, and primary sclerosing cholangitis, and clinical trials of therapies

196 Patients with autoimmune hepatitis, primary sclerosing cholangitis, and primary biliary cirrhosis as

197 rent autoimmune hepatitis, recurrent primary sclerosing cholangitis, and recurrent primary biliary ci

198 including primary biliary cirrhosis, primary sclerosing cholangitis, biliary atresia, and progressive

199 CC, including parasitic infections, primary sclerosing cholangitis, biliary-duct cysts, hepatolithia

200 rable with those in patients without primary sclerosing cholangitis, but there is a higher rate of re

201 may play a role in biliary atresia, primary sclerosing cholangitis, cellular rejection, and primary

202 atment of primary biliary cirrhosis, primary sclerosing cholangitis, cholestasis of pregnancy, and dr

203 atment of primary biliary cirrhosis, primary sclerosing cholangitis, cholestasis of pregnancy, total

204 including primary biliary cirrhosis, primary sclerosing cholangitis, chronic hepatitis C, and postnec

205 r data collected included history of primary sclerosing cholangitis, family history of colorectal can

206 ure research efforts should focus on primary sclerosing cholangitis, in addition to primary biliary c

207 sights have arisen from studies of secondary sclerosing cholangitis, in which a similar clinical prof

208 s such as primary biliary cirrhosis, primary sclerosing cholangitis, intrahepatic cholestasis of preg

209 malignant PVT, after exclusion of those with sclerosing cholangitis, liver transplants, choledocholit

210 4 patients included autoimmune pancreatitis, sclerosing cholangitis, lymphoplasmacytic aortitis, sali

211 ing pancreatitis and cholangitis, n = 21; b) Sclerosing cholangitis, n = 9; c) Sclerosing pancreatiti

212 ectable or arising in the setting of primary sclerosing cholangitis, neoadjuvant chemoradiotherapy fo

213 in nonalcoholic fatty liver disease, primary sclerosing cholangitis, neonatal hemochromatosis, acute

214 vancements in the areas of childhood primary sclerosing cholangitis, nonalcoholic fatty liver disease

215 st LT for primary biliary cirrhosis, primary sclerosing cholangitis, or alcoholic cirrhosis (group I)

216 Underlying primary sclerosing cholangitis, percutaneous biliary intubation,

217 Yet different from patients with primary sclerosing cholangitis, the expression of CCL25 remained

218 ease, non-alcoholic steatohepatitis, primary sclerosing cholangitis, total parenteral nutrition-assoc

219 emonstrated in biliary lithiasis and primary sclerosing cholangitis, two cholangiopathies regarded as

220 icult, particularly in patients with primary sclerosing cholangitis, who are at risk of developing th

221 Primary sclerosing cholangitis-inflammatory bowel disease probab

222 vealed pancreatic duct strictures in two and sclerosing cholangitis-like appearance in one.

223 ous complications in patients with secondary sclerosing cholangitis.

224 static entities, primary (PSC) and secondary sclerosing cholangitis.

225 Still rarer is its presentation as sclerosing cholangitis.

226 ones, primary biliary cirrhosis, and primary sclerosing cholangitis.

227 ngitis and the steroid-nonresponsive primary sclerosing cholangitis.

228 from UC that is not associated with primary sclerosing cholangitis.

229 f 38.5% observed among patients with primary sclerosing cholangitis.

230 n haplotypes are not associated with primary sclerosing cholangitis.

231 itis, primary biliary cirrhosis, and primary sclerosing cholangitis.

232 nancy, primary biliary cirrhosis and primary sclerosing cholangitis.

233 on does not appear to directly cause primary sclerosing cholangitis.

234 ve been detected in liver tissues in primary sclerosing cholangitis.

235 ancy, primary biliary cirrhosis, and primary sclerosing cholangitis.

236 established long-term treatment for primary sclerosing cholangitis.

237 ociation studies as risk factors for primary sclerosing cholangitis.

238 on in a patient with sickle cell disease and sclerosing cholangitis.

239 nset or immediately in patients with primary sclerosing cholangitis.

240 amilial intrahepatic cholestasis and primary sclerosing cholangitis.

241 MC mediators may be therapeutic for primary sclerosing cholangitis.

242 f ERC, especially in patients with secondary sclerosing cholangitis.

243 iary tuberculosis with features of secondary sclerosing cholangitis.

244 response such as alcoholic liver disease or sclerosing cholangitis.

245 kocytes, and abrogates progression of murine sclerosing cholangitis.

246 t both primary biliary cirrhosis and primary sclerosing cholangitis.

247 ity of primary biliary cirrhosis and primary sclerosing cholangitis.

248 tal antimicrobials were those with secondary sclerosing cholangitis.

249 e most studied medical treatment for primary sclerosing cholangitis; pilot studies suggest a possible

250 do not confer any susceptibility to primary sclerosing cholangitis; the role of intercellular adhesi

251 /=1 per 4 mm(2)) and 37% with nonspecific or sclerosing chronic sialadenitis (NS/SCS).

252 eased with declining CD4 counts, but nodular sclerosing decreased more precipitously than mixed cellu

253 te to the pathogenesis of podocyte injury in sclerosing glomerulopathies such as focal segmental glom

254 able glomerular injury in diabetes and other sclerosing glomerulopathies.

255 and kidney biopsy analysis showed a nodular sclerosing GN with extensive focal global glomeruloscler

256 ical examination diagnosed Hodgkin's nodular sclerosing histological subtype disease has been establi

257 Medial canthal BCCs, morpheaform, or sclerosing histology were not more common in the recurre

258 With more severe immunosuppression, nodular sclerosing HL becomes infrequent, explaining the higher

259 p24.1 amplification is restricted to nodular sclerosing HL, the cHL subtype most closely related to M

260 Nodular sclerosing Hodgkin lymphoma (NSHL) is a distinct, highly

261 , in fact, closely resemble those of nodular sclerosing Hodgkin lymphoma (NSHL).

262 lymphoma that is closely related to nodular sclerosing Hodgkin's lymphoma.

263 yndrome caused by stage 2A, grade I, nodular sclerosing Hodgkin's lymphoma.

264 NT FINDINGS: Emerging evidence suggests that sclerosing idiopathic orbital inflammation can be an IgG

265 Sclerosing idiopathic orbital inflammation is a rare dis

266 Sclerosing idiopathic orbital inflammation is a rare, di

267 arge, controlled study comparing the various sclerosing idiopathic orbital inflammation treatments ar

268 patients and immunoglobulin (Ig) G4-related sclerosing inflammation in 7 patients.

269 (P = 0.002, Fisher exact test), but not with sclerosing inflammation present in 28% (13 of 46).

270 was greater than after resection of nodular-sclerosing lesions (33.5 months, P = 0.013).

271 Of six radial sclerosing lesions associated with the original 88 lesio

272 olycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL).

273 Sclerosing lymphoplasmacytic inflammation at almost any

274 imens of IgA nephropathy and one specimen of sclerosing membranoproliferative GN, showed bright (2-3+

275 Sclerosing mesenteritis (SM) is sometimes used as an umb

276 rosis, reactive nodular fibrous pseudotumor, sclerosing mesenteritis, and membranous glomerulonephrit

277 rs were reexamined and classified as nodular-sclerosing (no component of papillary carcinoma) or papi

278 n = 9; c) Sclerosing pancreatitis, n = 4; d) Sclerosing pancreatitis and cholangitis with pancreatic

279 Where discernible, disease was a) Sclerosing pancreatitis and cholangitis, n = 21; b) Scle

280 angitis with hepatic pseudotumour, n = 3; f) Sclerosing pancreatitis with pancreatic pseudotumour, n

281 n divided into subtypes 1 (lymphoplasmacytic sclerosing pancreatitis) and 2 (idiopathic duct centric

282 n = 21; b) Sclerosing cholangitis, n = 9; c) Sclerosing pancreatitis, n = 4; d) Sclerosing pancreatit

283 Subacute sclerosing panencephalitis (SSPE) is a fatal complicatio

284 Subacute sclerosing panencephalitis (SSPE) is a progressive fatal

285 quela of measles virus infection is subacute sclerosing panencephalitis (SSPE), a fatal disease of th

286 virus infection of the brain causes subacute sclerosing panencephalitis (SSPE), a progressive, relent

287 tal neurodegenerative complication, subacute sclerosing panencephalitis (SSPE), occurs during persist

288 ls from the brain of a patient with subacute sclerosing panencephalitis (SSPE).

289 ls from the brain of a patient with subacute sclerosing panencephalitis, and single-cell RT-PCR was u

290 7 of 14 cases with MS and 1 case of subacute sclerosing panencephalitis, but not in IgG from noninfla

291 ognized measles virus, the cause of subacute sclerosing panencephalitis.

292 esions were diagnosed as papilloma (n = 29), sclerosing papilloma (n = 8), and benign papillary lesio

293 he presence of small lesions indicative of a sclerosing process were detected, which were undetectabl

294 ed in 70% HG was superior to 75% HG alone in sclerosing reticular veins, with no statistical differen

295 metaphyseal dysplasia (FMD) is a progressive sclerosing skeletal dysplasia affecting the long bones a

296 carcinoma to that of the more common nodular-sclerosing subtype.

297 Patients with papillary and nodular-sclerosing tumors had similar demographics, operative pr

298 pillary tumors compared with the more common sclerosing tumors.

299 utcome compared with the more common nodular-sclerosing type.

300 The most common of these include the diffuse sclerosing variant, tall cell variant, and insular thyro